Therakind

Therakind is a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient populations, including children and the elderly.

The company has obtained regulatory approvals for three products across the FDA, EMA and MHRA, and has developed a proprietary intranasal dry powder delivery platform available for co-development across a range of molecules.

A parallel programme targets novel antimicrobial agents against WHO-priority drug-resistant pathogens.